Early Results from Transdermal Estrogen PATCH trial - 2

[janebob99]

Here's some charts comparing Lupron ADT to transdermal estrogen (TDE) therapy for High Risk and Very High Risk men with prostate cancer.

The upper chart shows the percentage of men that have been castrated to a testosterone level < 50 ng/dL after 1 month of treatment. For Lupron, only 65% of HR/VHR men were effectively castrated, compared to 83% of men treated with TDE. So, TDE can be more effective at castration than Lupron in this study.

The lower chart shows the level of estradiol (picomol/L) after 1 month of treatment. The Lupron level is about 60, while the high-dose level is much higher, about 840 (pico mol/L) (i.e., supra-physiologic).

The normal range for men is from 35 to 175 (pico mol/L). Lupron reduces testosterone, which, in turn, reduces estradiol in the Lupron arm

Bob